Meeting
2012 Genitourinary Cancers Symposium
Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.
Authors
Deborah Mukherji
The Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom
Deborah Mukherji , Carmel Jo Pezaro , Diletta Bianchini , Andrea Zivi , Johann Sebastian De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 17)
DOI
10.1200/jco.2012.30.5_suppl.17
Abstract #
17
Poster Bd #
B2
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Prospective evaluation of low-dose ketoconazole plus hydrocortisone (HC) in chemotherapy-pretreated castration-resistant prostate cancer (CRPC) patients.
First Author: Ernest N. Lo
First Author: Johann S. De Bono
Poster
2016 ASCO Annual Meeting
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.
First Author: Mary-Ellen Taplin
Poster
2014 ASCO Annual Meeting
Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study.
First Author: Robert B. Montgomery